Neil Culligan, MD
Neurology · Danbury, CTNPI 1649275611
Payments from drug & device makers
Across 81 payments — averaging $18.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$200
- Supernus Pharmaceuticals, Inc.$141
- Argenx US, Inc.$121
- Eisai Inc.$95
- UCB, Inc.$94
- Lundbeck LLC$75
- plus $792 from 26 others
What the payments were for
- Food & beverage$1,518100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 12 | $200 |
| Supernus Pharmaceuticals, Inc. | 8 | $141 |
| Argenx US, Inc. | 1 | $121 |
| Eisai Inc. | 4 | $95 |
| UCB, Inc. | 5 | $94 |
| Lundbeck LLC | 4 | $75 |
| Grifols USA, LLC | 4 | $72 |
| EMD Serono, Inc. | 5 | $71 |
| AstraZeneca | 3 | $71 |
| Amgen | 3 | $55 |
| Acadia Pharmaceuticals Inc | 4 | $53 |
| GE HealthCare | 3 | $53 |
| CSL Behring | 2 | $47 |
| Jazz Pharmaceuticals Inc. | 2 | $35 |
| Portola Pharmaceuticals, LLC | 2 | $31 |
| Adlon Therapeutics L.p. | 2 | $30 |
| Biogen | 2 | $28 |
| Vanda Pharmaceuticals Inc. | 1 | $26 |
| Ipsen Biopharmaceuticals, Inc | 1 | $24 |
| Sunovion Pharmaceuticals Inc. | 1 | $19 |
| SK Life Science, Inc. | 1 | $18 |
| Neurocrine Biosciences, Inc. | 1 | $18 |
| Mallinckrodt Enterprises LLC | 1 | $17 |
| Medtronic | 1 | $17 |
| Bausch Health US, LLC | 1 | $17 |
| Upsher-smith Laboratories LLC | 1 | $15 |
| AbbVie | 1 | $15 |
| Johnson & Johnson | 1 | $13 |
| Assertio Therapeutics, Inc. | 1 | $13 |
| Strongbridge US Inc. | 1 | $11 |
| Vertical Pharmaceuticals, LLC | 1 | $11 |
| Sanofi | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VYVGART$121
How this compares
$1,518 in reported general payments places this provider in the 45th percentile of 280 neurology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BetaseronInterferon Beta-1b | 11 | $98,939 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 11 | $53,292 |
| Gabapentin | 229 | $4,537 |
| Lacosamide | 18 | $2,486 |
| Azathioprine | 38 | $2,381 |
| Donepezil Hcl | 190 | $2,260 |
| Levetiracetam | 89 | $2,079 |
| Pyridostigmine Bromide | 31 | $1,966 |
| Nortriptyline Hcl | 73 | $1,134 |
| Topiramate | 35 | $1,028 |
| Pregabalin | 25 | $910 |
| Memantine Hcl | 29 | $639 |
| ClopidogrelClopidogrel Bisulfate | 38 | $522 |
| RizatriptanRizatriptan Benzoate | 17 | $501 |
| Lamotrigine | 11 | $501 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Grifols USA, LLCGamunex-C | $72 | $53,29211 claims |
| Upsher-smith Laboratories LLCTopiramate | $15 | $1,02835 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 280 neurology providers in Connecticut.
Other neurology in Danbury
- Robert BonwetschDanbury$246K
- Samuel MarkindDanbury$220K
- David GrecoDanbury$76K
- Behzad Habibi KhamenehDanbury$74K
- Charles GuardiaDanbury$64K
- David RussellNew Haven$31.2M
- Peter McAllisterFairfield$15M
- Erin LongbrakeNorth Haven$5.5M
- David HaflerNew Haven$3.5M
- Stewart TepperStamford$1.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.